Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 ibrexafungerp maintenance study in recurrent vulvovaginal candidiasis
2019-002600-40Phase 3Completed
- Sponsor
- SCYNEXIS, Inc.
- Start
- Oct 2019
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in recurrent vulvovaginal candidiasis (RVVC) and vulvovaginal candidiasis (VVC) comparing Ibrexafungerp with Placebo (2 arms). Primary endpoint: Clinical success up to test of cure at Week 24. Started Oct 2019; status: completed.
02
Drugs
ibrexafungerp
03
Conditions
recurrent vulvovaginal candidiasis (RVVC)vulvovaginal candidiasis (VVC)
Beyond the preview
Go deeper on 2019-002600-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002600-40.